A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Enfortumab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sitravatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Mirati Therapeutics
- 07 May 2024 Planned number of patients changed from 200 to 55.
- 07 May 2024 Planned End Date changed from 19 Apr 2024 to 19 Apr 2025.
- 07 May 2024 Planned primary completion date changed from 19 Apr 2024 to 19 Apr 2025.